45results about How to "Meet medicinal requirements" patented technology

The invention provides a method for preparing Linezolid. The preparation method has the advantages of few total reaction steps of the synthetic route, high yield, mild reaction of each step of the synthesis, no need of special reagent and device, and simple operation, and is suitable for large scale industrial production. High-purity of Linezolid can be prepared by the method, and medicinal requirements can be satisfied.

The invention relates to a preparation method of a bulk drug of mitiglinide calcium used for treating type 2 diabetes mellitus. The mitiglinide calcium is prepared by a series of reaction steps comprising using D-phenylalanine as a starting material, esterification and cis-hexahydroisoindoline reaction. In the reaction, the problem of high cost of special equipment for high pressure hydrogenation and operation as well as chiral catalyst in the traditional process can be solved, the use of chiral resolution and a resolving agent is avoided, and the yield is improved.

The invention discloses a preparation method of high-purity vinpocetine. The preparation method comprises the following steps: S1, preparing vincamine, wherein tabersonine is dissolved, a hydrogenation reaction is performed under the catalysis of palladium and carbon to obtain vincadifformine, the vincadifformine is oxidized to obtain a vincadifformine nitric oxide, and an intermediate vincamine is obtained from the vincadifformine nitric oxide reaction liquid under the catalysis of an acid; S2, dewatering the vincamine by using toluene as a solvent and adding a dewatering agent to obtain apovincamine; and S3, on the basis of the step S2, carrying out a transesterification reaction by taking ethanol as a solvent, using dichloromethane as a cosolvent and using sodium ethoxide / sodium methoxide as a catalyst to obtain a vinpocetine crude product, and re-crystallizing with ethanol to obtain vinpocetine. The process provided by the invention has the advantages of simple production operation, avoidance of high-toxicity reagents, less impurity of the obtained product, high production efficiency, simple and convent operation and environmental friendliness, wherein the purity of the productis more than 99.9%, the quality of the product is higher than the quality of the product obtained by the original research factory, and the medicinal requirements are met.

The invention relates to a crystal form of a renal outer medullary potassium channel inhibitor and a preparation method of the crystal form. Specifically, the invention relates to an IV crystal form of an L-tartrate of a renal outer medullary potassium channel (ROMK) inhibitor and a preparation method of the IV crystal form. The IV crystal form has good chemical stability and crystal form stability, a used crystallization solvent is low in toxicity and residue, and the IV crystal form can be better used for clinical treatment.

The present invention relates to an I-type crystal of L-alanine-(14-oridonin) ester trifluoroacetate and a preparation method therefor.The preparation method comprises crystallizing a L-alanine-(14-oridonin) ester trifluoroacetate solid in any crystal form or amorphous form in a single organic solvent or a mixed organic solvent thereof to obtain the I-type crystal of the L-alanine-(14-oridonin) ester trifluoroacetate.The I-type crystal of the L-alanine-(14-oridonin) ester trifluoroacetate obtained in the present invention has a good crystal form stability and chemical stability, and uses a crystallization solvent which has a low toxicity and low residue, and can be better used in clinical treatments.

The invention provides a method for preparing Linezolid. The preparation method has the advantages of few total reaction steps of the synthetic route, high yield, mild reaction of each step of the synthesis, no need of special reagent and device, and simple operation, and is suitable for large scale industrial production. High-purity of Linezolid can be prepared by the method, and medicinal requirements can be satisfied.

The invention discloses a rapid melting misoprostol vaginal composition which comprises the following components according to weight percent: 0.1 to 2 percent of misoprostol-Hydroxypropyl methyl cellulose, 78 to 98 percent of loading agents, 0.2 to 10 percent of disintegrating agents and 1 to 10 percent of lubricant, wherein the misoprostol vaginal composition contains 25 microgramme. The invention further discloses a preparation method and application of the rapid melting misoprostol vaginal composition. the rapid melting misoprostol vaginal composition provided by the invention targetedly avoids that conventional magnesium stearate is taken as lubricant, and the prepared composition is good in content uniformity, so that the dose is ensured accuracy, and the composition is completely applicable to labor induction of late pregnancy and satisfies the requirements on safety and reliability for medicinal use.

A preparing method of a lenalidomide-nicotinamide eutectic composition is disclosed. The lenalidomide-nicotinamide eutectic composition adopts lenalidomide as a medicine active component, adopts nicotinamide as an eutectic forming component, and is prepared by mixing the lenalidomide and the nicotinamide according to a ratio into an organic solvent, stirring and reacting through adopting a slurry crystallization process. The lenalidomide-nicotinamide eutectic composition prepared by the slurry crystallization process has better stability, higher solubility and a higher dissolution rate than lenalidomide-nicotinamide eutectic compositions prepared through conventional grinding methods, and is hoped to improve bioavailability and medicine effects of the lenalidomide and to meet medicinal requirements of the lenalidomide.

The invention provides a method of recycling divalproex sodium crystallization mother liquor. The method comprises the following steps: (1), concentrating the divalproex sodium crystallization mother liquor to obtain a solid-state mixture containing divalproex sodium; (2), carrying out acidizing treatment onto the solid-state mixture obtained in the step (1), controlling pH to 0.5-4.5 to obtain an organic layer; and (3), carrying out fractionation onto the organic layer obtained in the step (2) to obtain valproic acid. Yield of the valproic acid obtained by the method disclosed by the invention can be as high as 95%, and purity of the valproic acid is not lower than 99.1%, so that medicinal requirements can be satisfied. Moreover, the method disclosed by the invention is simple and easy to implement and easy to control in a reaction process, lowers actual production cost, and satisfies large-scale industrial production requirements.

The invention relates to multiple crystal forms of S-Montelukast sodium and a preparation method thereof, in particular to a crystal form II, a crystal form III and a crystal form IV of S-Montelukast sodium, the preparation method of the crystal forms, pharmaceutical composition containing the crystal forms and a medical application of the crystal forms and the pharmaceutical composition. The crystal form II, the crystal form III and the crystal form IV of S-Montelukast sodium have excellent physicochemical properties and good stability, and are suitable for a preparation technological process and long-term storage. The pharmaceutical composition adopting compounds in the crystal forms as active components can be used for treating diseases such as hypertension and the like.

The present invention relates to a crystal form A of ertacarline hydrochloride and a preparation method thereof. The crystal form A of ertacarline hydrochloride obtained in the present invention has good crystal form stability and chemical stability, and has good bioavailability It can be better used in clinical treatment.

The invention relates to a preparation method of chloromethyl hexafluoroisopropyl ether. Specifically, the present invention relates to a method for preparing chloromethyl hexafluoroisopropyl ether, wherein the solvent used in the reaction contains chloromethyl hexafluoroisopropyl ether. The preparation method introduces its own product as a solvent, which not only solves the solidification phenomenon of the reaction system during the reaction process, but also greatly improves the purity of the product, which is beneficial to industrial production.

The invention relates to a sulfate of an intestine type 2B sodium phosphate co-transporter inhibitor and its crystal form and particularly relates to N1-methyl-N1-(2-morpholin-ethyl)-N3-(3-(4-phenethylphenylcarbamoyl)-4, 5, 6, 7-tetrahydrobenzo[b]thiophene-2-yl)-m-phthalamide sulfate (compound shown in the formula (I)) and its type I crystal and preparation method. The type I crystal of the compound shown in the formula (I) has good chemical stability and crystal form stability and the used crystallization solvent has low toxicity and low residue content and can be used for clinical treatment.